ArticleReproductive health2026
Age at menopause and risk of sarcopenia in postmenopausal women: evidence from the China health and retirement longitudinal study.
Article in Reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMenopausal age is closely associated with women's health, but research on its association with sarcopenia risk remains insufficient. Our study aimed to explore how menopausal age affects the risk of sarcopenia in postmenopausal women.
methodsBased on the China Health and Retirement Longitudinal Study (CHARLS) database, we included 3,410 postmenopausal women from 2011-2015. Participants were divided into five groups according to menopausal age: premature menopause (< 40 years), early menopause (40-44 years), intermediate menopause (45-49 years), normal menopause (50-55 years), and late menopause (> 55 years). Sarcopenia was identified using the 2019 Asian Working Group for Sarcopenia (AWGS 2019) criteria. Mixed-effects logistic regression models were used to analyze the association between menopausal age and sarcopenia.
resultsThe study included 3,410 postmenopausal women with a mean age of 64.39 ± 8.68 years and overall sarcopenia prevalence of 35.40%. Compared to the average age at menopause group (50-55 years; 1,593/3,410; 46.70%), premature menopause (127/3,410; 3.70%), early menopause (385/3,410; 11.30%), intermediate menopause (1,098/3,410; 32.20%), and late menopause (207/3,410; 6.10%) were all associated with increased sarcopenia risk. Compared to normal menopause (50-55 years), early menopause (40-44 years), intermediate menopause (45-49 years), and late menopause (> 55 years) were associated with statistically significant increased sarcopenia risk, while premature menopause (< 40 years) showed a non-significant elevated risk (OR = 1.40, 95% CI: 0.89-2.21, p = 0.1438). This association was stronger among women with late menarche, rural residence, married status, non-retirement, or low education levels.
conclusionsBoth earlier and later than average menopausal age may be associated with increased sarcopenia risk in Chinese postmenopausal women, although the association for premature menopause did not reach statistical significance in fully adjusted models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.